

## Symbols in Product Labeling

<b>REF</b>	Catalog number		Consult instructions for use
<b>IVD</b>	In vitro diagnostics medical device		Use by (last day of the month)
<b>CONT.</b>	Contents of kit		Caution
<b>AC.</b>	Accessory		Manufacturer
<b>Adaptor</b>	Adaptor		Temperature limitation
<b>Holder</b>	Holder		
<b>LOT</b>	Batch code		
<b>EC REP</b>	Authorized Representative in the European Community		
<b>BL</b>	Blank		
<b>CAL</b>	Calibrator		
<b>CONTROL</b>	Control		
<b>CONC.</b>	Assigned value		

### Intended use

The μTASWako DCP Immunological Test System is an *in vitro* device that consists of reagents used with the μTASWako i30 Immunoanalyzer to quantitatively measure, by immunochemical techniques, des-γ-carboxy-prothrombin (DCP) in human serum. The device is intended for *in vitro* diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma (HCC) in conjunction with other laboratory findings, imaging studies and clinical assessment.

### Summary and explanation of the test

Prothrombin is a vitamin K dependent blood coagulation factor that is formed in the liver. It contains 10 γ-carboxy-glutamic acid (Gla) residues on its amino-terminal domain, which are synthesized from glutamic acid (Glu) residues by vitamin K dependent γ-glutamyl carboxylase in a posttranslational process<sup>(1,2,3)</sup>. In the case of deficiency of vitamin K or the ingestion of vitamin K antagonists (Warfarin sodium), DCP is found in patients.

DCP was reported by Liebman et al., in 1984 as a specific tumor marker that increases in patients with hepatocellular carcinoma (HCC)<sup>(4)</sup>. A number of reports have shown elevation in serum DCP levels in patients with HCC and liver cirrhosis<sup>(5,6)</sup>. Also, DCP does not correlate with AFP and AFP-L3%. DCP and AFP-L3% are considered complementary assays for assessing the risk of developing HCC<sup>(7,8)</sup>. When used in combination, a greater number of patients at risk of developing HCC were identified resulting in more treatment options for a larger number of patients.<sup>(7,8)</sup>

### Principle of the method

The μTASWako DCP assay is an easy-to use system with all reagents in a single cartridge and each assay performed on a single, disposable "chip" using microfluidic electrophoretic separation<sup>(9)</sup>. After placing sample, reagent cartridge, Wash Solution and Chip Cassette in the instrument, the buffers, antibody solutions and sample are automatically dispensed into appropriate chip wells. The sample and Dye-Fab' solution are dispensed and form the primary immunocomplex (Dye-Fab' – DCP) in the well. Each solution is loaded into the microfluidic channel by vacuum. Voltage is applied to the chip and DNA-Fab' moves to anode and is concentrated by isotachopheresis. The concentrated DNA-Fab' reacts with the primary immunocomplex and forms the secondary immunocomplex (Dye-Fab' – DCP – DNA-Fab'). The secondary immunocomplex is further concentrated during isotachopheresis to the anode and is thereby separated from unbound Dye-Fab'.

The concentrated secondary immunocomplexes are separated from unbound Dye-Fab' by capillary gel electrophoresis. The Dye-Fab'-labeled DCP is detected by laser-induced fluorescence. The concentration is proportional to the fluorescence. All reactions, separations and detection occur on a microfluidic chip.

### Reagents

The μTASWako DCP kit contains a reagent cartridge and an adapter. The reagent cartridge contains the following buffers and antibodies for conducting 100 tests.

(1) Electrophoresis Buffer (R1)	5.4 mL
100 mmol/L Tris buffer, pH 7.9	
(2) Electrophoresis Buffer (R2)	4.4 mL
40 mmol/L Tris buffer, pH 8.0	
(3) Electrophoresis Buffer (R3)	2.6 mL
75 mmol/L Tris buffer, pH 7.1	
(4) Labeled Antibody Solution (C1)	0.77 mL
75 mmol/L Good's buffer, pH 6.0	
200 nmol/L Anion-conjugated anti human DCP antibody (mouse monoclonal antibody) (DNA-Fab' (DCP))	
(5) Labeled Antibody Solution (C2)	0.92 mL
26.5 mmol/L Good's buffer, pH 5.8	
1000 nmol/L Fluorescent dye labeled anti human prothrombin antibody (mouse monoclonal antibody) (Dye-Fab' (prothrombin))	
(6) Fluorescent Dye Solution (FD)	1.4 mL
50 mmol/L Good's buffer, pH 6.0	

Store the reagent cartridge at 2–10°C (Do not freeze).



Reagent allocation in the reagent cartridge

### Accessory

Adapter (Reagent cartridge opener) 1 piece

### Warning and precautions

#### Precautions for assay

- (1) For *in vitro* diagnostic use.
- (2) Not to be used internally in humans or animals.
- (3) Store the reagents under the specified conditions. Do not use reagents past the expiration date stated on the reagent cartridge label or more than 30 days past the opening of the cartridge.

- (4) The presence of precipitates in the reagents or values of control sera outside the manufacturer's acceptable range may be an indication of reagent degradation.
- (5) Do not use the reagents described above for any purpose other than described herein.
- (6) Do not use the reagents described above in any procedures other than those described herein. Performance cannot be guaranteed if the reagents are used in other procedures.
- (7) Do not use reagents that were frozen. Such reagents may give false results.
- (8) After opening reagents, place the reagents onto the instrument immediately. Once the reagents are opened, they must be stored on the  $\mu$ TASWako i30.
- (9) Do not use the cartridge, the adapter and other materials in the kit for any purpose other than those described herein.
- (10) Operate the instrument according to the Instruction Manual.
- (11) Do not reuse chips or sample cups.
- (12) Calibration material is sold separately. For the usage of calibration material, refer to its package insert.
- (13) It is recommended that specimen collection be carried out in accordance with CLSI Document M29-A3 and other national safety regulations. No known test method can offer complete assurance that human blood samples will not transmit infection. Therefore, all blood derivatives should be considered potentially infectious.
- (14) FDA UDI (Unique Device Identification) is on the box. Keep box until reagent is finished.

### Precautions for protection from hazards

- (1) If the reagents come in contact with mouth, eye, or skin, wash the exposed area immediately with plenty of water. Consult a physician if necessary.
- (2)  $\mu$ TASWako Wash Solution is 0.5 mol/L NaOH, pH 11 or higher. If the reagent comes in contact with the mouth, eye, or skin, wash off immediately with plenty of water. Consult a physician if necessary.
- (3) All serum samples, and apparatuses that may be contaminated with serum, should be treated with caution to avoid infection.

### This product contains components classified as follows according to the European Regulation :

#### Hazard designation of product



Warning

#### Mixture containing :

5-Chloro-2-methyl-2H-isothiazol-3-one [EC No 247-500-7] and 2-Methyl-2H-isothiazol-3-one [EC No 220-239-6] (3:1)

#### Information pertaining to particular dangers for man and environment

#### Hazard statement

May cause an allergic skin reaction.

#### Precautionary statement

Avoid breathing vapours/spray.

Contaminated work clothing should not be allowed out of the workplace.

Wear protective gloves/ protective clothing/ eye protection.

If on skin : Wash with plenty of soap and water.

If skin irritation or rash occurs : Get medical advice/attention.

Wash contaminated clothing before reuse.

Dispose of contents or container in accordance with local/regional/national/international regulation.

#### Precautions for disposal

- (1) Dispose of reagents according to your local or national regulations.
- (2) Wear lab protective gear when disposing of the waste liquid, used chips and sample cups to avoid infection.

#### Limitations of the procedure

- (1) Heterophilic antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with *in vitro* immunoassays. Samples from patients routinely exposed to animals or animal serum products can demonstrate this type of interference potentially causing an anomalous result. The  $\mu$ TASWako DCP has been formulated to minimize the risk of the interference ; however, potential interactions between rare sera and ingredients can occur. For diagnostic purposes, the results obtained from this assay should always be used and interpreted in conjunction with the clinical examination, patient medical history, and other findings.
- (2) It is recommended that this assay be used in conjunction with imaging studies for clinical diagnosis.
- (3) DCP producing tumors other than HCC can show elevated values of DCP.

- (4) Liver disease caused by other etiologies such as alcohol liver disease, hemochromatosis, Wilson's disease, autoimmune hepatitis and steatohepatitis have not been studied with this assay. The results obtained from this assay should always be used in combination with the clinical examination, patient medical history, and other findings.
- (5) Medication containing vitamin K preparations may cause a negative bias on the DCP values.
- (6) Medication containing vitamin K antagonist or antibiotic may cause a positive bias on the DCP values.

### Instruments

The  $\mu$ TASWako DCP kit is designed to be used with the automated analyzer " $\mu$ TASWako i30". Refer to the Instruction Manual for a description of instrument operation and specifications.

### Specimen collection and preparation

- (1) Use serum as a specimen.
- (2) If immediate analysis is not possible, store specimen at  $-80^{\circ}\text{C}$ . DCP concentration in serum is stable for 4 years frozen at  $-80^{\circ}\text{C}$ . DCP in serum is stable up to 3 weeks at  $-20^{\circ}\text{C}$ . DCP in serum is stable for 1 week at  $4^{\circ}\text{C}$ .

### Procedure for $\mu$ TASWako i30

#### Materials supplied

Refer to the section entitled "Reagents".


#### Materials required but not supplied (purchased separately)

$\mu$ TASWako i30  
 $\mu$ TASWako DCP Calibrator Set  
 $\mu$ TASWako DCP Control L  
 $\mu$ TASWako DCP Control H  
 $\mu$ TASWako Wash Solution  
 $\mu$ TASWako Chip Cassette  
 Sample Cup S  
 Pure Water

#### Reagent preparation

Reagents : Use as supplied. Unopened reagents are stable until expiration date printed on the label when stored at  $2-10^{\circ}\text{C}$ . Opened reagents can be used for 30 days on the  $\mu$ TASWako i30.

The unopened reagent cartridge is sealed with aluminum film. At the time of use, the adapter is placed on top of the reagent cartridge with the needle side downward then the aluminum seal is punctured by pressing the adapter through the cartridge completely. Lay the reagent cartridge on a flat surface when you open the reagent cartridge. Access holes are made by the needles and are used as passages for the pipetting probe. Seven access holes are observed on the reagent cartridge when above procedure is properly conducted. Do not remove the adapter after seal has been broken. Place the reagent cartridge onto the  $\mu$ TASWako i30 instrument according to the  $\mu$ TASWako i30 Instruction Manual. Store the reagent cartridge in the instrument.




Set an adapter on a reagent cartridge and fit into socket (1).

### Test procedure

Refer to " $\mu$ TASWako i30 Instruction Manual" for the details of assay procedure.

#### Reaction Outline



## Calibration

Calibration is required when reagent cartridge is opened. Calibration curve is automatically produced in the  $\mu$ TASWako i30 by plotting fluorescence intensity of the immunocomplex peak area vs. DCP concentrations of the calibrators. The calibration curve is stable for 30 days. For a detailed description on the calibration, refer to Section 4.2 "Calibration Operation" of the Instruction Manual.

## Quality control

A quality control program is recommended for all clinical laboratories. Daily analysis using Wako's  $\mu$ TASWako DCP Controls L and H is recommended for monitoring the performance of the procedure. The values obtained for the controls should fall within 15% for DCP across upper reportable range ( $\geq 1$  ng/mL) from the assigned values or within 20% for DCP across lower reportable range ( $< 1$  ng/mL) from the assigned values.

## Results

The final results are automatically calculated and printed out or sent out to the host computer. The results are reported as a concentration of DCP. Refer to Section 4.11 "Checking Test Results" of the Instruction Manual for the information on the calculation procedure and printout format.

## Reportable range

The reportable range of DCP concentration is 0.1 – 950 ng/mL. When the value exceeds 950 ng/mL, marks H! or HH! appears on the screen of  $\mu$ TASWako i30 and on paper printout. Dilute the sample with "Blank" in the  $\mu$ TASWako Calibrator Set to 950 ng/mL or less, re-assay and multiply an obtained result by dilution factor. The dilution factors are approximately 20-fold for H! and 200-fold for HH!. Refer to Section 4.11.3 "How to Check Printed Test Results" of the Instruction Manual for detailed information on the marks.

## Expected values

Less than 7.5 ng/mL (In-house data).

## Performance characteristics

### Dilution Recovery

The accuracy was demonstrated by the recovery study. The results of recovery (%) ranged from 94.0% to 111.6%.

Sample	Sample Series A (ng/mL)	Sample Series B (ng/mL)	After mixed Sample Series (A:B=9:1 mixed) Expected Value (ng/mL)	Obtained Value (ng/mL)	Recovery (%)
1	0.20	2.10	0.39	0.38 0.38	97.4 97.4
2	0.20	9.80	1.16	1.09 1.12	94.0 96.6
3	0.20	73.10	7.49	7.15 7.18	95.5 95.9
4	0.20	893.90	89.57	94.87 95.82	105.9 107.0
5	0.20	3639.00	364.08	374.13 376.92	102.8 103.5
6	7.80	9.80	8.00	8.12 8.17	101.5 102.1
7	7.80	73.10	14.33	14.13 13.82	98.6 96.4
8	7.80	893.90	96.41	96.87 99.88	100.5 103.6
9	7.80	3639.00	370.92	392.40 391.92	105.8 105.7
10	7.80	7565.60	763.58	782.87 809.56	102.5 106.0
11	100.84	893.90	180.15	183.26 181.28	101.7 100.6
12	100.84	3639.00	454.66	438.91 430.21	96.5 94.6
13	100.84	7565.60	847.32	924.94 945.39	109.2 111.6
14	307.19	893.90	365.86	357.92 362.80	97.8 99.2
15	307.19	1866.60	463.13	467.82 481.47	101.0 104.0
16	307.19	3639.00	640.37	667.58 671.57	104.2 104.9

## Precision

### [Within-run precision]

Within-run precision studies were performed for the DCP assay over the reportable range using 4 serum samples and 2 levels of controls. The results of CV% for each sample measured in 21 replicates ranged from 1.1% to 6.7%. This study was conducted in accordance with CLSI EP5-A2.

No.	Replicate	Mean (ng/mL)	SD (ng/mL)	CV (%)
Serum 1	21	0.18	0.012	6.7
Serum 2	21	1.05	0.017	1.6
Serum 3	21	6.70	0.076	1.1
Serum 4	21	914.98	14.039	1.5
Control L	21	1.00	0.018	1.8
Control H	21	22.63	0.256	1.1

### [Total precision]

Total precision studies were performed for the DCP assay over the reportable range using 7 pooled human serum samples and 2 levels of controls. Three samples (5, 6 and 7) were pooled human serum samples near the clinical decision point and were prepared without spiking with analyte. The results of CV%, measured over 21 days, for all samples ranged from 1.3% to 7.9%. This study was conducted in accordance with CLSI EP5-A2.

No.	Number of assay days	Mean (ng/mL)	ST (ng/mL)	CV (%)
Serum 1	21	0.19	0.015	7.9
Serum 2	21	1.04	0.035	3.4
Serum 3	21	6.70	0.135	2.0
Serum 4	21	917.94	14.847	1.6
Serum 5	21	6.91	0.24	3.5
Serum 6	21	7.22	0.21	2.9
Serum 7	21	7.57	0.23	3.0
Control L	21	1.05	0.024	2.3
Control H	21	22.74	0.303	1.3

## Linearity

The assay was verified to be linear for the reportable ranges of 0.1 – 950 ng/mL according to CLSI EP6-A.

## Limit of Detection

The limit of detection (LoD) study was carried out consistent with CLSI EP17-A "Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline" (Vol. 24, No. 34, 2004). From the results, the LoD for DCP was found by calculation using the equation given in CLSI EP-17A (section 4.3.2) because data distributions were Gaussian. The LoD, the point at which the analytes are distinguished from blank, was found to be 0.042 ng/mL.

## Interference testing

Potential interfering substances listed below were evaluated by determining recovery in the presence of known amounts of these substances. No significant effect from the potential interferents occurred. This study was conducted in accordance with CLSI EP7-A.

### ① Hemoglobin

Hemoglobin	(mg/dL)	0	193.3	386.6	579.9	773.2	966.5
	(ng/mL)	4.81	4.83	4.84	4.88	4.82	5.12
DCP	Recovery (%)	100.0	100.4	100.6	101.5	100.2	106.4

### ② Bilirubin

Bilirubin	(mg/dL)	0	7.5	15.0	22.5	30.0	37.5	79.4
	(ng/mL)	5.00	4.97	4.83	4.75	4.66	4.66	4.70
DCP	Recovery (%)	100.0	99.4	96.6	95.0	93.2	93.2	94.0

### ③ Conjugated bilirubin

Conjugated bilirubin	(mg/dL)	0	8.4	16.8	25.3	33.7	42.1	84.2
	(ng/mL)	5.36	5.25	5.10	5.06	5.07	4.73	4.65
DCP	Recovery (%)	100.0	97.9	95.1	94.4	94.6	88.2	86.8

### ④ Triglycerides

Triglycerides	(mg/dL)	0	45.2	90.4	135.6	180.8	226.0	452.0
	(ng/mL)	5.83	5.91	5.87	5.91	5.81	5.82	5.99
DCP	Recovery (%)	100.0	101.4	100.7	101.4	99.7	99.8	102.7

### ⑤ Ascorbic acid

Ascorbic acid	(mg/dL)	0	10	20	30	40	50
	(ng/mL)	6.42	6.70	6.60	6.81	7.01	6.98
DCP	Recovery (%)	100.0	104.4	102.8	106.1	109.2	108.7

⑥ Rheumatoid factor

Rheumatoid factor	(IU/mL)	0	100	200	300	400	500
DCP	(ng/mL)	6.15	6.16	6.32	6.21	6.25	6.25
	Recovery (%)	100.0	100.2	102.8	101.0	101.6	101.6

⑦ Acetaminophen

Acetaminophen	(mg/dL)	0	4	8	12	16	20
DCP	(ng/mL)	5.03	5.05	4.98	5.04	4.92	5.05
	Recovery (%)	100.0	100.4	99.0	100.2	97.8	100.4

⑧ Ibuprofen

Ibuprofen	(mg/dL)	0	10	20	30	40	50
DCP	(ng/mL)	6.36	6.09	6.37	6.80	6.85	6.79
	Recovery (%)	100.0	95.8	100.2	106.9	107.7	106.8

⑨ Acetylsalicylic acid

Acetylsalicylic acid	(mg/dL)	0	10	20	30	40	50
DCP	(ng/mL)	6.33	6.15	6.37	6.28	6.38	6.48
	Recovery (%)	100.0	97.2	100.6	99.2	100.8	102.4

⑩ Vitamin B1

Vitamin B1	(mg/dL)	0	10	20	30	40	50
DCP	(ng/mL)	5.67	5.63	5.53	5.66	5.65	5.67
	Recovery (%)	100.0	99.3	97.5	99.8	99.6	100.0

⑪ Vitamin B6

Vitamin B6	(mg/dL)	0	10	20	30	40	50
DCP	(ng/mL)	5.66	5.59	5.61	5.58	5.54	5.61
	Recovery (%)	100.0	98.8	99.1	98.6	97.9	99.1

⑫ Vitamin B12

Vitamin B12	(mg/dL)	0	10	20	30	40	50
DCP	(ng/mL)	5.86	5.92	5.86	5.87	5.85	5.80
	Recovery (%)	100.0	101.0	100.0	100.2	99.8	99.0

⑬ Interferon  $\alpha$

Interferon $\alpha$	(IU/mL)	0	600	1200	1800	2400	3000
DCP	(ng/mL)	6.22	6.43	6.31	6.35	6.36	6.31
	Recovery (%)	100.0	103.4	101.4	102.1	102.3	101.4

⑭ Interferon  $\beta$

Interferon $\beta$	(IU/mL)	0	600	1200	1800	2400	3000
DCP	(ng/mL)	6.14	6.23	6.08	6.16	6.17	6.34
	Recovery (%)	100.0	101.5	99.0	100.3	100.5	103.3

⑮ Interferon  $\gamma$

Interferon $\gamma$	(JRU/mL)	0	600	1200	1800	2400	3000
DCP	(ng/mL)	6.13	6.22	6.34	6.11	6.01	6.34
	Recovery (%)	100.0	101.5	103.4	99.7	98.0	103.4

**Interference testing with high concentration of DCP samples.**

Potential interfering substances listed below were evaluated by determining recovery in the presence of known amounts of these substances. No significant effect from the potential interferents occurred. This study was conducted in accordance with CLSI EP7-A.

① Hemoglobin

Hemoglobin	(mg/dL)	0	1060
DCP	(ng/mL)	125.9	124.3
	Recovery (%)	100.0	98.7

② Bilirubin

Bilirubin	(mg/dL)	0	75
DCP	(ng/mL)	108.2	118.4
	Recovery (%)	100.0	109.5

③ Conjugated bilirubin

Conjugated bilirubin	(mg/dL)	0	80
DCP	(ng/mL)	106.9	101.7
	Recovery (%)	100.0	95.2

④ Triglycerides

Triglycerides	(mg/dL)	0	452
DCP	(ng/mL)	135.4	135.3
	Recovery (%)	100.0	100.0

⑤ Rheumatoid factor

Rheumatoid factor	(IU/mL)	0	500
DCP	(ng/mL)	159.9	161.7
	Recovery (%)	100.0	101.1

**Correlation**


A comparison of the  $\mu$ TASWako DCP to a similar DCP assay (LBA DCP) was performed using  $\mu$ TASWako i30 and LiBASys, respectively. A comparison study of 200 samples from 100 patients was conducted by both instruments. In addition, 20 serum samples spiked with DCP to cover the upper part of the reportable range were studied.

Deming analysis shows acceptable correlation with and without spiked samples, as demonstrated in the correlation graphs given herein. Correlation #1 shows the Deming regression analysis of DCP values, with spiked samples, run on  $\mu$ TASWako i30 and LiBASys. Correlation #2 shows the Deming regression analysis of DCP values, without spiked samples.

Additionally, a calculation of an estimate of agreement is given to describe how often the  $\mu$ TASWako DCP test agrees with the comparative test, DCP assay (LBA DCP). Using the data from correlation #2 and the clinical cut-off value of 7.5 ng/mL, a concordance rate (overall agreement) of 95.5% is found.


**Correlation #1**

Number	220	
Intercept	-0.94	95% CI (-2.09 to 0.21)
Slope	1.04	95% CI (1.00 to 1.08)



**Correlation #2**

Number	200	
Intercept	0.61	95% CI (-0.50 to 1.72)
Slope	0.95	95% CI (0.85 to 1.04)



**DCP 2x2 Agreement**

		LiBASys	
		$\geq 7.5$ ng/mL	$< 7.5$ ng/mL
$\mu$ TASWako i30	$\geq 7.5$ ng/mL	77 (38.5%)	5 (2.5%)
	$< 7.5$ ng/mL	4 (2.0%)	114 (57.0%)

Percent positive agreement = 95.1%  
 Percent negative agreement = 95.8%  
 Overall agreement = 95.5%

## Clinical Information Collected with LIBASys

Longitudinal data were collected on 441 subjects with liver disease from seven clinical sites. The study subjects consisted of 324 males and 117 females, with an average age of 52.6 years and ranged from 40 to 70 years. Serum was collected at an average interval of 138 days.

The study subjects were categorized into three groups based on biopsy, explanted liver histology and imaging results. Group A patients developed confirmed HCC during study and with lesions of at least 0.5 cm in diameter. Group B patients were suspected of possible HCC with lesions at least 0.3 cm in diameter and high DCP results. Group C patients did not have HCC. The risk of developing HCC among patients with an elevation of DCP at or above 7.5 ng/mL, and among patients without such an elevation is calculated, along with their 95% confidence interval using DCP results from Group A and Group C. The risk of developing HCC with an elevated DCP test result is 36.5%. The risk of developing HCC with a negative DCP test result is 7.6%. Their ratio is 4.8, indicating a 4.8 fold increase of developing HCC given an elevated DCP test result.

Group		A	C	Total	B
		HCC	No HCC		Suspicious*
DCP	≥7.5 ng/mL	19	33	52	7
	<7.5 ng/mL	20	244	264	64
Total		39	277	316	71

Relative risk : 4.8 (95% C.I. : 2.8–8.4)  
 Risk of HCC given DCP positive : 36.5% (95% C.I. : 23.5%–49.6%)  
 Risk of HCC given DCP negative : 7.6% (95% C.I. : 4.4%–10.8%)

\*The patients categorized as "Suspicious" (far right column) were treated as a separate study group because no definitive diagnosis could be obtained from the physicians. However, for demonstrative purposes, these patients were included in the analysis to illustrate the effect of this regrouping on the relative risk calculations. The worst case and the best case scenarios are shown in the following two tables.

Best case scenario		HCC	No HCC	Total
DCP	≥7.5 ng/mL	19+7=26	33	59
	<7.5 ng/mL	20	244+64=308	328
Total		46	341	387

Relative risk : 7.2 (95% C.I. : 4.3–12.1)  
 Risk of HCC given DCP positive : 44.1% (95% C.I. : 31.4%–56.7%)  
 Risk of HCC given DCP negative : 6.1% (95% C.I. : 3.5%–8.7%)

Worst case scenario		HCC	No HCC	Total
DCP	≥7.5 ng/mL	19	33+7=40	59
	<7.5 ng/mL	20+64=84	244	328
Total		103	284	387

Relative risk : 1.3 (95% C.I. : 0.8–1.9)  
 Risk of HCC given DCP positive : 32.2% (95% C.I. : 20.3%–44.1%)  
 Risk of HCC given DCP negative : 25.6% (95% C.I. : 20.9%–30.3%)

## References

- (1) Bajaj S.P., et al., J. Biol. Chem., **257**, 3726-3731 (1982)
- (2) Poser J.W., et al., J. Biol. Chem., **254**, 431-436 (1979)
- (3) Olson, R.E., et al., Annu. Rev., Nutr., **4**, 281-337 (1984)
- (4) Liebman, H.A., et al., N Engl. J. Med., **310**, 1427-1431 (1984)
- (5) Okuda, H., et al., Cancer, **85**, 812-818 (1999)
- (6) Koike, Y., et al., Cancer, **91**, 561-569 (2001)
- (7) Sassa, T., et al., Eur. J. Gastroenterol. Hepatol., **11**, 1387-1392 (1999)
- (8) Shimauchi, Y., et al., Oncol. Rep., **7**, 249-256 (2000)
- (9) Kagebayashi C., et al., Anal. Biochemistry, **388**, 306-311 (2009)

## Ordering information

Code No.	Wako Product	Package
995-60701	μTASWako DCP	100 Tests
999-61201	μTASWako DCP Calibrator Set	1 Set
	Blank (3 × 2 mL)	
	Calibrator 1 (1 × 2 mL)	
995-61301	μTASWako DCP Control L	4 × 2 mL
991-61401	μTASWako DCP Control H	4 × 2 mL
991-60801	μTASWako Wash Solution	4 × 60 mL
993-61601	μTASWako Chip Cassette	5 × 20 Pieces
452-00501	Sample Cup S	1000 Pieces

Revision date ; Sep. 20, 2016



μTASWako i30, its IVD reagent kits and the consumables developed by Wako use Wako's proprietary LBA-EATA assay technologies and microfluidic technologies licensed from Caliper Life Sciences, Inc.

## Manufactured by Wako Pure Chemical Industries, Ltd.

1-2 Doshomachi 3-Chome, Chuo-Ku Osaka 540-8605 Japan  
 Tel : +81-6-6203-3749  
 Fax : +81-6-6203-1917  
 www.wako-chem.co.jp

## Distributed by Wako Diagnostics Wako Life Sciences, Inc.

1025 Terra Bella Ave., Suite A  
 Mountain View, CA 94043 USA  
 Tel : 877-714-1924  
 Fax : 804-271-0449  
 www.wakodiagnostics.com

## Authorized representative in the European Community Wako Chemicals GmbH

Fuggenstraße 12,  
 D-41468 Neuss, Germany  
 Telephone : +49(0)2131/311-176  
 Facsimile : +49(0)2131/311-100  
 www.wako-chemicals.de

16.10.14K08